

HAMED ISMAIL ALI

Assistant Professor

Rangel College of Pharmacy; Texas A& M University-Health Science Center.

1010 West Avenue B; Kingsville, TX 78363-8202, USA

E-mail: alyismail@tamu.edu

Web: <https://pharmacy.tamhsc.edu/directory/ali.html>

Tel: (361)-221-0758

EDUCATION

- 2003-2007 **Ph.D. Pharmaceutical Sciences** (Medicinal Chemistry, Pharmacology, and Drug Design).
College of Pharmaceutical Sciences, Okayama Univ., JAPAN
- 1996-.2001 **M.S. in Pharmaceutical Chemistry**
College of Pharmacy, Helwan Univ., Cairo, Egypt.
- 1983-1988 **B.S. Pharmacy**, (Valedictorian)
College of Pharmacy, Tanta Univ., Tanta, Egypt

PROFESSIONAL EXPERIENCE

- 8/2015- Present **Assistant Professor**; Rangel College of Pharmacy of Pharmacy, Texas A&M Univ. Health Science Center, USA.
- 5/2014- 7/2015 **Instructional Assistant Professor**; Rangel College of Pharmacy of Pharmacy, Texas A&M Univ. Health Science Center, USA.
- 1/2014-5/2014 **Lecturer**; Dept. of Pharmaceutical Sciences, Rangel College of Pharmacy of Pharmacy, Texas A&M Univ. Health Science Center, USA.
- 8/2013-10/2013 **Instructor**; Dept. of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Univ. Health Science Center, USA.
- Fall 2013 **Adjunct Faculty**; Dept. of Chemistry, College of Arts and Sciences, Texas A&M Univ.-(TAMUK), USA.
- 1/2013-12/2013 **Postdoctoral Research Associate**; Rangel College of Pharmacy, Texas A&M Univ. Health Science Center, USA.
- 2013-Present **Associate Professor**; College of Pharmacy, Helwan Univ., Cairo, Egypt.
- 2010-2012 **Assistant Professor**; College of Pharmacy, Umm Al-Qura Univ., KSA.
- 2009-2010 **Assistant Professor**; College of Pharmacy, Omar Al-Mukhtar University.
- 2008-2009 **Adjunct Faculty**; College of Pharmacy, Univ. of Modern Sciences and Arts (MSA), 6th October City, Egypt
- 2007-2009 **Adjunct Faculty**; College of Pharmacy, Misr International Univ. (MIU), Cairo, Egypt.
- 2007-2009 **Lecturer**; College of Pharmacy, Helwan Univ., Cairo, Egypt.
- 1-3/2006 **Visiting Scholar**; College of Pharmaceutical Sciences, Kobe Gakuin Univ., Japan.
- 2001-2003 **Assistant Lecturer**; College of Pharmacy, Helwan Univ., Cairo, Egypt.
- 1995-2001 **Instructor**; College of Pharmacy, Helwan Univ., Cairo, Egypt.

LEADERSHIP EXPERIENCE & SERVICES

2018-present	Senator, Texas A&M University Senate, College Station, Texas
2018-present	TAMU Academic Affairs Committee, Texas A&M University, College Station, Texas
2018-present	TAMU First Year Experience (FYE) Student Advisory Committee, Texas A&M University, College Station, Texas
2017-2019	Chair and Co-Chair of the Admission Committee, Rangel College of Pharmacy, Texas
2016-2017	Member of the OAC (Outcome Assessment Committee), Rangel College of Pharmacy, Texas
2016-present	Member of the Instructional Venues Advisory <i>Ad hoc</i> Committee, Rangel College of Pharmacy, Texas
2018-2019	Member of Experiential Education Committee, Rangel College of Pharmacy, Texas
April-May, 2018	Chair of the Scientific Committee for the 45 th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature. Texas A&M Irma Lerma Rangel College of Pharmacy College Station, Texas, May 23-25, 2018
2017-present	Co-advisor for NCPA (National Community Pharmacists Association)
2011-2012	Head of Dept. of Clinical pharmacy; College of Pharmacy, Umm Al-Qura Univ., KSA.
1996-present	Pharmacy Manager/Registered Pharmacist; Cairo, Egypt

SPECIAL TECHNICAL SKILLS

- Strong experience in multistep Pharmaceutical Syntheses, overlapped with intensive protocols of various drug design approaches.
- Strong experience in handling Accelrys Discovery Studio Molecular Modeling program versions (1.1~3.5) software, Accelrys Inc., San Diego, CA, USA. With two training courses 2005 in Osaka and 2006 in Okayama Univ.
- Expertise in handling MOE and Cache and Biomed Cache program pro version 6.1.10
- Strong experience in Virtual Screening to get best hits and optimized to get Lead compound involving different Computational Chemical Methods, in addition to Homology modeling techniques.
- Strong experience in AutoDock 3.05, 4.2, and Vina; a Grid-Based Docking program; for docking of flexible ligand into rigid or flexible protein. Involving both of Linux, and Windows OS.
- Strong experience in operating and interpreting JASCO FT/IR, Varian VXR and Bruker 300 and 500 MHz ¹H and ¹³C NMR spectrometers, and Yanaco CHN Corder MT-5 apparatus for Microanalysis.
- Strong experience in operating GOLD 5.1 for docking of flexible ligand into rigid or flexible protein. Involving both of Linux, and Windows OS.
- Strong experience in operating CobiFlash Rf (TeleDyne ISCO) for automatic column chromatographic separation of synthesized compounds.

RESEARCH & ENHANCEMENT GRANTS AWARDED

Current Funded Projects

- | | |
|-----------|--|
| 2018-2020 | Title: ASPIR ² E: Aggie Student Pharmacists Initiative for Recruitment / Retention and Education.
Fund: 152,000 USD; by Texas Higher Education Coordinating Board Minority Health Research And Education Grant Program |
|-----------|--|

Role: Coaching for Organic and Introductory Medicinal chemistry Course

- 05/01/2018 - **Title:** "Incorporating Innovative IPE between Pharmacy and Other Health-Related
04/30/2019. Disciplines into Pharmacy Curriculum to Explore Multiple Public Health Challenges"
Fund: 18,000 USD; by The Division of Research funds the Program to Enhance
Scholarly and Creative Activities (PESCA).
Role: PI
- 08/15/2018 - **Title:** New Insights into the role of Transmembrane and Tetratricopeptide Repeat
08/14/2019. Containing 4 (TMTC4) as a potential marker and therapeutic target in breast cancer.
Fund: 36,000 USD; by the Discovery Foundation, Dallas, Texas.
Role: Co-PI
- 07-01-2018 - **Title:** Small Molecule Inhibitors of Ras•Sos
06-30-2019 **Fund:** 30,000 USD; by Texas A&M Triads for Transformation - T3 - Texas A&M
University.
Role: Co-PI

Completed Funded Projects

Notice: The funds from Universities in the Mid-East were not transferrable to USA, except only one grant.

- 2012-2018 **Title:** "*Preparation and development through computer-aided molecular drug design of isoxazolidine nucleosides and isoxazolidinyl and nucleosidyl podophylloxin derivatives with potential antiviral and anticancer activities*"
Fund: 535,000 USD, by King Abdul-Aziz City for Science and Technology (KACST), KSA;
Role: CO- I.
- 2012-2018 **Title:** "*Plants with Potential Anti-cancer Effect: Phytochemical, Biological and Mechanistic Studies. Development of the Production of Active Natural Compounds in vitro and the Optimization of the Biological Activity by Chemical Modifications*".
Fund: 535,000 USD, by King Abdul-Aziz City for Science and Technology (KACST), KSA.
Role: CO- I
- 2013-2018* **Title:**" *Computer Aided Drug Design and Synthesis of Hybrid Flavin Analogs with Flexible Moieties as Potent Antitumor Agents*"
Fund: 80,000 USD, by Institute of Scientific Research, KSA.
Role: PI
- *This project was partially transferred to Rangel College of Pharmacy, TAMHSC for collaboration by synthesis of biologically active derivatives.
- 2013-2016 **Title:**" *Safe anti-inflammatory: design, synthesis and biological evaluation of some novel pyrrolizine derivatives as anti-inflammatory agents*"
Fund: 43,000 USD, by Institute of Scientific Research, KSA.
Role: CO- I.
- 2015-2016 **Title:**" *Computer Aided Drug Design and Synthesis of Hybrid Flavin Analogs with Flexible Moieties as Potent Antitumor Agents*"
Fund: 30,000 USD, Grant was transferred from Umm Al Qura Univ. to Rangel College of Pharmacy, TAMHSC, USA.
Role: PI

Hamed I. Ali, BPharm, MPharm, PhD. C.V.

- 2015-2017 **Title:** *"Recent approach in cancer treatment: Design, synthesis and biological evaluation of novel pyrrolizine derivatives as potential multi-target kinase inhibitors"*.
Fund: 533,000 USD, by King Abdul-Aziz City for Science and Technology (KACST), KSA.
Role: **Consultant**
- 2012-2013* **Title:** *"Bioinformatics and Biotechnology Enhanced Drug Design and Synthesis of Flavin Analogs as Novel Potent Antitumor Agents"*
Fund: 530,000 USD, by King Abdul-Aziz City for Science and Technology (KACST), KSA;
Role: **PI**
- *This project is currently frozen due to my leave to USA.
- 2011-2012 **Title:** *"Antibacterial and antifungal activity of two types of Saudi propolis for oral microorganisms"*.
Fund: 50,000 USD, by Institute of Scientific Research, KSA.
Role: **CO- I**; Group leader in drug design implementation team.
- 2010-2012 **Title:** *"Computer aided drug design and synthesis of potent anti-HCV benzimidazoles and quinoxalines"*.
Fund: 460,000 USD, by Science and Technology Development Fund (STDF), Egypt.
Role: Group leader in drug design implementation team.
- 2011-2014 **Title:** *"Anticancer Drug approach: Computer-aided drug design, Synthesis and Preclinical Evaluation of New Benzimidazoles as Checkpoint Kinase 2 (chk2) Inhibitor"*.
Fund: 305,000 USD, by Science and Technology Development Fund (STDF), Egypt.
Role: Group leader in drug design implementation team.

HONORS AND AWRADS

- Aug. 2019 **"2019-Texas A&M University-Distinguished Achievement Award: College Level"**.
The Association of Former Students honors outstanding faculty members for their dedication to teaching. Recipients are recognized for their talent, expertise, and devotion on conveying knowledge to students.
- May, 2019 Honors: **"Teaching Team of the Year"** for the Infectious Disease Course. Irma Lerma Rangel, College of Pharmacy, Texas A&M University, Health Science Center.
- May, 2018 Honors: **"Teaching Team of the Year"** for the Infectious Disease Course. Irma Lerma Rangel, College of Pharmacy, Texas A&M University, Health Science Center.
- May, 2017 Honors: **"Teacher of the Year"**. Irma Lerma Rangel, College of Pharmacy, Texas A&M University, Health Science Center.
- May, 2017 Honors: **"Teaching Team of the Year"** for the Infectious Disease Course. Irma Lerma Rangel, College of Pharmacy, Texas A&M University, Health Science Center.
- May, 2016 Honors: **"Teaching Team of the Year"** for the Infectious Disease Course. Irma Lerma Rangel, College of Pharmacy, Texas A&M University, Health Science Center.
- May, 2015 Honors: **"Teaching Team of the Year"** for the Infectious Disease Course. Irma Lerma Rangel, College of Pharmacy, Texas A&M University, Health Science Center.

- May, 2014 Honors: **"Teaching Team of the Year"** for the Infectious Disease Course. Irma Lerma Rangel, College of Pharmacy, Texas A&M University, Health Science Center.
- Jun. 2013 **First Place** in Poster Competition; 2013 Research Colloquium, Texas A&M University, Health Science Center, Irma Lerma Rangel, College of Pharmacy, 2013, Jun. 27-28.
- 2012 Outstanding Researcher Award, College of Pharmacy, Umm Al-Qura Univ., KSA.
- 2010 OMSA Merit Award, Okayama Student Association of Okayama Univ., Japan.
- 2009 Best Lecturer Merit Award, Omar Al-Mukhtar Univ., College of Pharmacy, Al-Beida-Libya.
- 2008-2009 Doctor of the Year Award, elected by students, Helwan Univ., Egypt.
- 2003-2007 National Egyptian Governmental Scholarship for the Ph.D. degree in Japan
- 2008 **First Place** in poster presented in the 1st Scientific Conference of College of Pharmacy, Cairo Univ., Egypt
- 1988 Award for The Valedictorian position for five years continuously in college of Pharmacy, sponsored by Egyptian Syndicate of Cairo pharmacists.

LIST OF PUBLICATIONS

PEER REVIEWED PUBLICATIONS

* Corresponding author

1. Omaima M Abdelhafez*, Eman Y Ahmed, Nehad A Abdel Latif, Reem K Arafa, Zakaria Y Abd Elmageed, **Hamed I. Ali***. *Design and Molecular Modeling of Novel P38 α MAPK Inhibitors Targeting Breast Cancer, Synthesized from Oxygen Heterocyclic Natural Compounds.* Bioorg. Med. Chem. 2019, 27, 1308-1319
2. Waleed H. Malki, Ahmed M. Gouda, Hamdy E.A. Ali, Rabaa Al-Rousan, Doaa Samaha, Ashraf N. Abdalla, Juan Bustamante J, Zakaria Y. Abd Elmageed, **Hamed I. Ali***. *Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition.* Eur J Med Chem. 2018, 152, 31-52.
3. Hamdy E. A. Ali, Pei-Yau Lung, Andrew B. Sholl, Shaimaa A. Gad, Juan J. Bustamante, **Hamed I. Ali**, Johng S. Rhim, Gagan Deep, Jinfeng Zhang, Zakaria Y. Abd Elmageed. *Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients.* Sci Rep. 2018, 8, 6335.
4. Farah D.; **Hamed I. Ali**; Abisola T.; Kara R.; Jihad. A, Ayman A. K. *LY2087101 and dFBr share transmembrane binding sites in the (α 4) β 2 Nicotinic Acetylcholine Receptor.* Sci Rep. 2018, 8, 1249.
5. Shadia A. Galal, Sarah H.M. Khairat , **Hamed I. Ali**, Samia A. Shouman, Yasmin M. Attia, Mamdouh M. Ali, Abeer E. Mahmoud, Abeer H. Abdel-Halim, Amal A. Fyiad, Ashraf Tabll, Reem El-Shenawy, Yasmine S. El Abd, Raghda Ramdan, Hoda I. El-Diwani. *Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors.* Eur. J. Med. Chem., 2018, 144, 859-873.
6. Kamelia M Amin, Yasmin M Syam, Manal M Anwar, **Hamed I Ali**, Tamer M Abdel-Ghani, Aya M Serry. *Synthesis and molecular docking study of new benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38 α MAP kinase inhibitors.* Bioorg. Chem. 2018,76, 487-500.

7. Hamdy E.A. Ali, Pei-Yau Lung, Andrew B. Sholl, Shaimaa A. Gad, Juan J. Bustamante, **Hamed I. Ali**, John S. Rhim, Gagan Deep, Jinfeng Zhang, Zakaria Y. Abd Elmageed. *Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients*. Sci Rep. 2018, Submitted with response to reviewers.
8. H. Badshah , B. Ali, S.A. Shah, M.M. Alam, H.I. Aly , A.S. Mumtaz. *First record of Morchella pulchella from Pakistan*. Mycotaxon, 2018, 133, 201–207
9. Ahmed M. Gouda*, Ahmed H. Abdelazeem, Hany A. Omar, Ashraf N. Abdalla, Mohammed A.S. Abourehab, **Hamed I. Ali***. *Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action*. Bioorg. Med. Chem., 2017, 25, 5637-5651
10. Hamdy EA Ali, Shaimaa A Gad, Gagan Deep, **Hamed I. Ali**, Zakaria Y. Abd Elmageed. *Molecular insights into the role of exosomes in health disparity of prostate cancer*. Cancer Health Disparities. 2017. 1: E1-113 DOI: 10.9777/CHD.2017.10002
11. Kamelia M Amin, Yasmin M Syam, Manal M Anwar, **Hamed I Ali**, Tamer M Abdel-Ghani, Aya M Serry, *Synthesis and molecular docking studies of new furochromone derivatives as p38 α MAPK inhibitors targeting human breast cancer MCF-7 cells*. Bioorg. Med. Chem., 2017, 25, 2423-2436.
12. Shadia A. Galal, Ahmed S. Abdelsamie, Samia A. Shouman, Yasmin M. Attia, **Hamed I. Ali**, Ashraf Tabll, Reem El-Shenawy, Yasmine S. El Abd, Mamdouh M. Ali, Abeer E. Mahmoud, Abeer H. Abdel-Halim, Amal A. Fyiad, Adel S. Girgis, Hoda I. El-Diwani. *Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs*. Eur. J. Med. Chem., 2017, 134, 392-405
13. Shaymaa kassab, Mohamed A Khedr, **Hamed I. Ali**, Mohamed M. Abdalla. *Discovery of New Rigid and Ring-Extended Analogs of Indomethacin with Potentially Selective Cyclooxygenase-2 Inhibition and Diminished PGE2 activities*. Eur. J. Med. Chem.. 2017, 141, 306-321
14. Majdi M. Bkhaitan, Agha Z. Mirza, Hina Shamshad, **Hamed I. Ali***. *Identification of Potent Virtual Leads and ADME Prediction of Isoxazolidine Podophyllotoxin Derivatives as Topoisomerase II and Tubulin Inhibitors*. J. Mol. Graph. Model, 2017, 73, 74–93.
15. Chang J. Qiao, **Hamed I. Ali**, Kwang H. Ahn, Srikanth Kolluru; Debra A. Kendall; Dia Lu, *Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor*. Eur. J. Med. Chem., 2016, 121, 517-529.
16. Ahmed M Gouda, **Hamed I. Ali**, Waleed H Almalki, Mohamed A Azim, Mohammed AS Abourehab, Ahmed H Abdelazeem. *Design, Synthesis, and Biological Evaluation of Some Novel Pyrrolizine Derivatives as COX Inhibitors with Anti-Inflammatory/Analgesic Activities and Low Ulcerogenic Liability*. Molecules, 2016, 21, 201-221. doi:10.3390/molecules21020201
18. Jian Zhang, **Hamed I Ali**, Yudhishtar Singh Bedi, Mahua Choudhury *The Plasticizer BBP Selectively Inhibits Epigenetic Regulator Sirtuins*. Toxicology, 2015, 338,130–141.
19. Omaima M. Abdelhafez, **Hamed I. Ali**, Kamelia M. Amin, Mohamed M. Abdalla, Eman Y. Ahmed. *“Design, synthesis and anticancer activity of furochromone and benzofuran derivatives targeting VEGFR-2 tyrosine kinase”*. RSC Advances, 2015, 5, 25312-25324.
20. Leepakshi K., **Hamed I. Ali**, Teresa Olszewska, Kwang H. Ahn, Aparna Damaraju, Debra A. Kendall, and Dai Lu, *“Structural Optimization of Indole-2-carboxamides Reveals Key Structure Activity Relationships for Allosteric Modulation of the Cannabinoid Receptor 1 (CB1)*, J. Med. Chem., 2014, 57, 3040–3052.

21. Ahmed T.; Yasser M. S.; Fatma A. F.; Mamdouh M. A.; **Hamed I. Ali**, Hoda I. El Diwani, "Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents" Eur. J. Med. Chem., 2014, 87, 868-880.
22. Omaima M. Abdelhafez, Kamelia M. Amin, **Hamed I. Ali**, Mohamed M. Abdalla, Eman Y. Ahmed; "Design, synthesis and anticancer activity of benzofuran derivatives targeting VEGFR-2 tyrosine kinase" RSC Adv., 2014, 4, 11569–11579
23. Ahmed T.; Yasser M. S.; Fatma A. F.; Mamdouh M. A.; Salwa M. S.; Jeremie M.; Gerhard W.; **Hamed I. Ali**; Hoda I. El Diwani, "Synthesis, Biological Evaluation, and Docking Studies of New 2-Furylbenzimidazoles as Anti-Angiogenic Agents: Part II" Arch. Pharm. Chem. Life Sci., 2014, 347, 1–14.
24. Radwan El-Haggar, Ola Ahmed Adel-Rasheed, Tamer Nasr, **Hamed. I. Ali**, Ayman Goudah, Nageh Abotaleb. *Synthesis, evaluation, and molecular docking studies for the anti-inflammatory activity of novel 8-substituted 7-benzoyloxy-4-methyl-6-nitrocoumarin derivatives*, Afr. J. Pharm. Pharmacol., 2014, 8, 1213-1227.
25. Mariam M. ; **Hamed I. Ali**; Kwang H. Ahn; Aparna Damaraju; Sushma Samala; Venkata K. Pulipati; Srikanth Kolluru; Debra A. Kendall; Dai Lu, "Structure–Activity Relationship Study of Indole-2-carboxamides Identifies a Potent Allosteric Modulator for the Cannabinoid Receptor 1 (CB1)" J. Med. Chem., 2013, 56, 7965–7975.
26. Kiran K.Vangara, **Hamed I. Ali**, Jingbo L. Liu, Dai Lu, Srikanth Kolluru, Srinath Palakurthi, "SN-38-Cyclodextrin Complexation and its Influence on the Solubility, Stability and In-Vitro Anticancer Activity against Ovarian Cancer". AAPS PharmSciTech, 2014, 15, 472–482.
27. Maha S. A., Gehan H. H., Magedda E. H., **Hamed I. Ali**, Nagy M. K., Abd El-mohsen M. S.. "Synthesis, Docking and Biological Activities of Novel Hybrids Celecoxib and Anthraquinone Analogs as potent cytotoxic agents". Int. J. Mol. Sci. 2014, 15, 22580-22603.
28. Omaima M. Abdelhafez, Kamelia M. Amin, **Hamed I. Ali**, Mohamed M. Abdalla, Rasha Z. Batran, "Monoamine oxidase – A and B inhibiting effect and molecular modeling of some synthesized coumarin derivatives", Neurochem. Internat., 2013, 62,198-209.
29. Omaima M. Abdelhafez, Kamelia M. Amin, **Hamed I. Ali**, Mohamed M. Abdalla, Rasha Z. Batran, "Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase a inhibitors", J. Med. Chem., 2012, 55, 10424–10436.
30. Gehan H.; Hegazy, **Hamed I. Ali***, "Design, synthesis, biological evaluation, and comparative cox1 and cox2 docking of p-substituted benzylidenamino phenyl esters of ibuprofenic and mefenamic acids", Bioorg. Med. Chem., 2012, Vol. 20, pp. 1259–1270.
31. Faizul A., Arwa M. Madi, **Hamed I. Ali**. "Molecular Docking And Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs That Block MAO-B and Adenosine A_{2A} Receptors for The Treatment of Parkinson's Disease". J. Young Pharmacists, 2012, 4,184-192.
32. Omaima M. Abdelhafez, Kamelia M. Amin, **Hamed I. Ali**, Timothy J. Maher, Rasha Z. Batran, "Dopamine release and molecular modeling study of some coumarin derivatives", Neurochem. Internat., 2011, 59, 906-912.

33. Faizul A.; Medapati V. V. Prasad, Neelaveni Thangavel, **Hamed I. Ali**, *Molecular docking studies of 1-(substituted phenyl)-3-(naphtha [1, 2-d] thiazol-2-yl) urea / thiourea derivatives with human adenosine A2A receptor*. Bioinformation, 2011, 6, 330–334.
34. **Hamed I. Ali**, M. Yamada, H. Fujita, Eiichi Akaho, “*Studies on 16 α -hydroxylation of steroid molecules and regioselective binding mode in homology-modeled cytochrome P450-2C11*”, Intern. J. Med. Chem., 2011, Article ID 918168, 1-11.
35. **Hamed I. Ali**, Tomohisa, Nagamatsu, Fujita, Eiichi Akaho, “*Structure-based drug design and AutoDock study of potential protein tyrosine kinase inhibitors*”, Bioinformation, 2011, 5, 368–364.
36. Mohsen M. Kamel, **Hamed I. Ali**, M. M. Anwar, N. A. Mohamed, A. M. Soliman, “*Synthesis, antitumor activity and molecular docking study of novel sulfonamide-schiff'sbases, thiazolidinones, benzothiazinones and their c-nucleoside derivatives*”, Eur. J. Med. Chem., 2010, 45, 572-580.
37. **Hamed I. Ali**, T. Fujita, E. Akaho, and T. Nagamatsu, “*Comparative AutoDock and PMF scoring functions and SAR of 2-substituted pyrazolotriazolopyrimidines and 4-substituted pyrazolopyrimidines as potent xanthine oxidase inhibitors*”, J. Comput. Aided Mol. Des., 2010, 24, 57– 75.
38. Ajaya R. Shrestha, **Hamed. I. Ali**, Noriyuki Ashida, Tomohisa Nagamatsu, “*Antitumor studies. Part 5: Synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins*”, Bioorg. Med. Chem., 2008,16, 9161– 9170.
39. **Hamed. I. Ali**, K. Tomita, E. Akaho, M. Kunishima, Y. Kawashima, T. Yamagishi, H. Ikeya, and T. Nagamatsu, “*Antitumor studies. Part 2: Structure-activity relationship study for flavin analogs including investigations on their in vitro antitumor assay and docking simulation into protein tyrosine kinase.*” Eur. J. Med. Chem., 2008, 43, 1376-1389.
40. **Hamed. I. Ali**, N. Ashida, T. Nagamatsu, “*Antitumor Studies. Part 4: design, synthesis, antitumor activity, and molecular docking study of novel 2-substituted 2-deoxoflavin-5-oxides, 2-deoxoalloxazine-5-oxides, and their 5-deaza analogs*”, Bioorg. Med. Chem., 2008, 16, 922–940.
41. K. Takamatsu, A. Takano, N. Yakushiji, K. Morishita, N. Matsuura, M. Makishima, **Hamed I. Ali.**, E. Akaho, A. Tai, K. Sasaki, H. Kakuta, “*Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype-preference: RXR α -preferential agonist possessing a sulfonamide moiety*”, ChemMedChem. 2008, 14, 454–460.
42. **Hamed. I. Ali**, N. Ashida, T. Nagamatsu, “*Antitumor studies. Part 3: design, synthesis, antitumor activity, and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(N-substituted amino)-10-alkyl-2-deoxo- 5-deazaflavins*”, Bioorg. Med. Chem., 2007, 15, 6336–6352.
43. X. Zheng, H. Oda, K. Takamatsu, Y. Sugimoto, A. Tai, E. Akaho, **Hamed. I. Ali**, T. Oshiki, H. Kakuta, and K. Sasaki, “*Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors*”, Bioorg. Med. Chem., 2007, 15, 1014-1021.
44. **Hamed. I. Ali**, K. Tomita, E. Akaho, H. Kambara, S. Miura, H. Hayakawa, N. Ashida, Y. Kawashima, T. Yamagishi, H. Ikeya, F. Yoneda, and T. Nagamatsu, “*Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deaza- flavins*”

and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents", Bioorg. Med. Chem., 2007, 15, 242–256.

45. H. Kambara, T. Yamada, M. Tsujioka, S. Matsunaga, R. Tanaka, **Hamed I. Ali**, C. Wiart, M. Yusof, H. Hassan, A. Hanifah, Z. M. Fauzi, N. H. Mazlan, M. Jay, M. Kunishima, and E. Akaho, "A study on medicinal plants from malaysia focused on *Acalypha Siamensis Oliv. ex Gage.* isolation and structure of a new tetraterpene, *Acalyphaser A*", ChemBiodivers, 2006, 3,1301–1306.
46. M. S. Rizk, S. S. Toubar, M. S. Abdel-Mottaleb, **Hamed I. Ali**, "A spectrofluorimetric determination of aminoglycoside antibiotics through reaction of their Ruhemann's purple with sodium borohydride", Bulletin of the College of Pharmacy (Cairo Univ.), 2003, 41, 141-148.
47. **Hamed I. Ali**, M. Yamada, Y. Fujita, Eiichi Akaho "studies on regioselective binding mode of steroid molecules in homology modeled cytochrome P450-2C11" naturePrecedings. : 2009 05:39 UTC; Posted 03 August 2009. hdl:10101/npre. 2009.3541.1.

PEER REVIEWED PUBLICATIONS IN PROCESS

48. Sawsan A. Mahmoud, Mosaad S. Mohamed, Nageh A. Abou Taleb, Noriyuki Ashida, Mohamed El-sawy, Tomohisa Nagamatsu, **Hamed I. Ali***. *Antitumor Studies: Design, Synthesis, Antitumor Activity and Molecular Docking Study of Novel 2-Deoxo-2-Substituted-5-Deazaalloxazines*, J. Bioorg. Chem. (in preparation).

LIST OF PRESENTATIONS at INTERNATIONAL, REGIONAL, and LOCAL MEETINGS

49. 18th Annual Team-Based Learning Collaborative TBLC Conference, March 14-16, 2019!TBLC 2019 Meeting, Renaissance Tampa International Plaza Hotel, Tampa, FL
50. Tamer Elwaie, Safinaz Abbas, Riham George, Enayat Ali, Rabaa Al-Rousan, Doaa Samaha, Zakaria Y. Abd Elmageed, **Hamed I. Ali***. Kinase-targeted cancer therapy: design, synthesis, and biological screening of ABL and EGFR/HER2 inhibitors. Podium presentation in 45th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature. Texas A&M Irma Lerma Rangel College of Pharmacy College Station, Texas, May 23-25, 2018
51. Ali HEA, Gaballa R, Sholl AS, Gaballah M, Bustamante J, Zanwar P, **Hamed I. Ali**, Abd Elmageed ZY. Exosomal microRNAs are associated with prostate cancer aggressiveness in African American patients. The 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. AACR meeting November 2-5, 2018, New Orleans, LA.
52. Gaballa R, Gaballah M, Ali HEA, Sholl AS, **Hamed I. Ali**, Abd Elmageed ZY. Exosomes-associated miR-5001, miR-3692 and miR-4529 are novel biomarkers for aggressive prostate cancer and associated with poor prognosis in African American patients. The 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. AACR meeting November 2-5, 2018, New Orleans, LA.
53. Asim Abu-Baker, Bryan Sigoloff, Zakaria Abd Elmageed, **Hamed I. Ali*** Identifying unique interprofessional education opportunity by exposing our pharmacy students to other non-healthcare disciplines. Nexus Summit 2018 (*National Center for Interprofessional Practice and Education*)- Creating Results: Interprofessional Vision to Action. Jul 29 - 31, 2018, Minneapolis, Minnesota.

54. Brian Standard, *Farah Deba*, **Hamed I. Ali**^{*}, Ayman K. Hamouda^{*}. Synthesis and pharmacological characterization of novel enhancers of neuronal nicotinic acetylcholine receptors. Podium presentation in 45th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature. Texas A&M Irma Lerma Rangel College of Pharmacy College Station, Texas, May 23-25, 2018.
55. **Hamed I. Ali**, *Our Current Participation and Approaches for Cancer Treatment. Journal Club May, 2, 2018. Rangel College of Pharmacy.*
56. Hamdy E.A. Ali, Pei-Yau Lung, Shaimaa Gad, Andrew S. Sholl, **Hamed I. Ali**, Jinfeng Zhang, Abd Elmageed, ZY. Transcriptome-wide profiling identifies novel differential genes associated with health disparity of prostate cancer. The 10th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. AACR meeting September 25-28, 2017, Atlanta, Georgia.
57. **Hamed Ali**, S. Galal; B. Standard; S. Khairat; M. Ali; R. El-Shenawy; S. Shouman; Y. Attia; R. Ramdan; H. El Diwani. Targeted cancer therapy: Novel Pyrazolobenzimidazole Conjugates as Checkpoint Kinase 2 (Chk2) Inhibitors Innovations in Cancer Prevention and Research Conference. Cancer Prevention & research Institute of Texas. November 13-14, 2017. Austin, Texas
58. Shaimaa A. Gad, Hamdy EA Ali, **Hamed Ismail-Aly**, Abd Elmageed, ZY. Exosomal microRNAs as a novel mechanism of resistance to BRAF-V600E inhibitor in melanoma cells. Innovations in Cancer Prevention and Research Conference. Cancer Prevention & research Institute of Texas. November 13-14, 2017. Austin, Texas
59. Hamdy E.A. Ali, Shaimaa Gad, Andrew B. Sholl, **Hamed I. Ali**, Abd Elmageed, ZY. Ornithine aminotransferase (OAT) and Adenosylmethionine decarboxylase 1 (AMD1) as novel genes associated with health disparity of prostate cancer. Innovations in Cancer Prevention and Research Conference. Cancer Prevention & research Institute of Texas. November 13-14, 2017. Austin, Texas
60. Shaimaa A. Gad, Hamdy EA Ali, **Hamed Ismail-Aly**, Abd Elmageed, ZY. The role of exosomes-associated microRNAs in developing drug resistance in melanoma. The 4th Annual Texas A&M University ENG-LIFE Workshop "Biomanufacturing and synthetic Biology". April 14, 2017. College Station, TX
61. **Hamed I. Ali**, Jan Poquiz, Zakaria Abd Elmageed, Asim Abu-Baker ^{*}, *Identifying unique interprofessional education opportunity by exposing our pharmacy students to other non-healthcare disciplines. 3rd Annual Interprofessional Education & Research Symposium (IPER 3), Texas A&M University-Health Science Center, Sept. 28, 2017.*
62. Brian Standard, Ahmed M. Gouda, Rabaa Al-Rousan, Doaa Samaha, Ashraf N. Abdalla, Zakaria Y. Abd Elmageed, Hamed I. Ali^{*} Structural-Based Design, Synthesis, SAR, and Biological Studies of Novel Alloxazine Analogues as Potent and Selective Antitumor Agents. Symposia on Cancer Research 2017 Cancer Metabolism, The University of Texas MD Anderson Cancer Center, Houston, Texas, October 5-6, 2017.
63. Brian Standard, Ahmed M. Gouda, Rabaa Al-Rousan, Doaa Samaha, Ashraf N. Abdalla, Zakaria Y. Abd Elmageed, **Hamed I. Ali**^{*} *Lead Optimization, Synthesis, In Silico, SAR, and Biological Studies of Novel Alloxazine Analogues as Potent and Selective Antitumor Agents. 43rd Annual MALTO Conference for the Medicinal Chemistry, University of Louisiana at Monroe, May 21-23, 2017.*
64. Hussain Badshah, **Hamed I. Ali**, Zakaria Abd Elmageed, Abdul Samad Mumtaz, *Phytochemical Screening of Selected Morchella Species for the Polysaccharide and Total Phenolic Contents and Their Potential Antioxidant and Antitumor Activities. Texas A&M ENG-LIFE 2017: Biomanufacturing and Synthetic Biology, April 14, 2017.*

65. **Hamed I. Ali**, Paul J. Dunnand, and Ayman K. Hamouda. *Design, Synthesis and Pharmacological Evaluation of Desformylflustrabromine Derivatives for Smoking Cessation*. Texas A&M University's first Engineering and Health Science symposium. Texas A&M University, Oct. 21, 2016.
66. **Hamed I. Ali**, Paul J. Dunnand, and Ayman K. Hamouda. *Design, Synthesis and Pharmacological Evaluation of Desformylflustrabromine (dFBr) Derivatives for Smoking Cessation*. Research Colloquium, Texas A&M University, Health Science Center, Irma Lerma Rangel, College of Pharmacy, Jun. 2-3, 2016.
67. Shaymaa Kassab, Walaa Bedewy, Waleed H. Malky, Ahmed M. Gouda, Zakaria Y Abd Elmageed, Rabaa Al-Rousan, Ashraf Abdalla, **Hamed I. Ali***. *Design, Synthesis, In Silico Study, and Biological Screening of Flavin Analogues as Novel Selective and Potent Antitumor Agents*. Research Colloquium, Texas A&M University, Health Science Center, Irma Lerma Rangel, College of Pharmacy, Jun. 2-3, 2016.
68. Jihad Ali, Walaa Bedewy, Waleed H. Malky, Ahmed M. Gouda, Zakaria Y Abd Elmageed, Rabaa Al-Rousan, Ashraf Abdalla, **Hamed I. Ali***. *Design, Synthesis, In Silico Study, and Biological Screening of Flavin Analogues as Novel Selective and Potent Antitumor Agents*. 43rd Annual MALTO Conference for the Medicinal Chemistry, in Houston University, May 23-24, 2016
69. **Hamed I. Ali**, Walaa A. Bedewy, Ahmed M. Abdelhameed, Mosaad S. Mohamed, Mohamed A. Elsayy, Tomohisa Nagamatsu. *Synthesis, Structural Anticancer Activity Relationship, and Docking Study of Novel 5-Deazaflavin Analogs*. 4th International Conference on Medicinal Chemistry & Computer Aided Drug Designing, Nov.2-4, 2015, Atlanta, GA, USA
70. Khurana, L., Ahn, K.H., **Ali, Hamed. I.**; Olszewska, T., Damaraju, A., Lu, D., Kendall, D.A. *Structure-Activity Relationships of Indole-2-Carboxamides Identifies Potent Allosteric Modulators of CB1 with Biased Agonism*. The 4th Annual AAPS-Northeastern Regional Symposium, CT. May 15th, 2015.
71. Sawsan A. Mahmoud, Mosaad S. Mohamed, Nageh A. Abou Taleb, Noriyuki Ashida, Mohamed Elsayy, Tomohisa Nagamatsu, **Hamed I. Ali***. *Antitumor Studies: Design, Synthesis, Antitumor Activity and Molecular Docking Study of Novel 2-Deoxo-2-Substituted-5-Deazaalloxazines*, 106th Annual Meeting of the American Association for Cancer Research, April 18-22, 2015, Philadelphia, PA, USA. Poster No. LB-098.
72. Lu D., **Ali H.**, Qiao C., Ahn K.H., Khurana L., Kendall D., *Design and Synthesis of Photoactivatable Affinity Ligands for CB1 Allosteric Site*, 2015 International Cannabinoid Research Symposium, June 29-July 03 Wolfville, Canada
73. Sunitha Meruvu, Jian Zhang, **Hamed. I. Ali**, Mahua Choudhury. *Benzyl butyl phthalate (BBP)-Foe or friend? An Epigenetic view*, Poster. *Texas A&M Nutrition Obesity Research–Mini-Symposium*, Oct. 31, 2014, Agrilife center, College Station, TX. USA.
74. **Hamed. I. Ali**, Srikanth Kolluru, Debra Kendall, Dai Lu, *Mapping the Allosteric Sites of Cannabinoid CB1 Receptors through Computational Methods*, 2013 **AAPS** Annual Meeting and Exposition, San Antonio, USA, 2013, Nov. 10-14, Poster No. T3001.
75. Kiran K. Vangara, **Hamed I. Ali**, Jingbo L. Liu, Dai Lu, Srikanth Kolluru, Srinath Palakurthi, *SN-38-Cyclodextrin Complexation: Influence on Solubility, Stability and In Vitro Anticancer Activity against Ovarian Cancer*, 2013 **AAPS** Annual Meeting and Exposition, San Antonio, USA, 2013, Nov. 10-14.

76. **Hamed. I. Ali**, Srikanth Kolluru, Debra Kendall, Dai Lu, Computer Aided Drug Design of Novel Allosteric Modulators of CB1, *2013 Research Colloquium, Texas A&M University, Health Science Center, Irma Lerma Rangel, College of Pharmacy, Kingsville, USA, 2013, Jun. 27-28*, book abstract page 25, poster No.1.
77. Aparna Damaraju, Sushma Samala, **Hamed. I. Ali**, S. Kolluru, Debra Kendall, Dai Lu, *Study of Structure Activity Relationship of CB1 of Allosteric Modulators ORG27546*, *2013 Research Colloquium, Texas A&M University, Health Science Center, Irma Lerma Rangel, College of Pharmacy, Kingsville, USA, 2013, Jun. 27-28*, book abstract page 28, poster No.15.
78. Aparna Damaraju, **Hamed. I. Ali**, S. Kolluru, D. Kendall, D. Lu, "*Study of Orthosteric and Allosteric Sites of Cannabinoid CB1 Receptors through Computational Methods*" The 18th Annual TAMHSC, Health Science Center, College of Medicine GSO Symposium, College Station, USA, 2013, Apr., 26, book abstract poster #31.
79. **Hamed. I. Ali**, S. Kolluru, D. Kendall, D. Lu, "*Study of Orthosteric and Allosteric Sites of Cannabinoid CB1 Receptors through Computational Methods*" The 18th Annual TAMHSC, Health Science Center, College of Medicine GSO Symposium, College Station, USA, 2013, Apr., 26, book abstract poster #31.
80. A. Damaraju, **Hamed. I. Ali**, S. Kolluru, D. Kendall, D. Lu, "*Structural Activity Relationship (SAR) Study of CB1 Allosteric Modulator ORG27569*". The 18th Annual TAMHSC, Health Science Center, College of Medicine GSO Symposium, College Station, USA, 2013, Apr., 26, book abstract poster #30.
81. Ajaya R. Shrestha, **Hamed. I. Ali**, Noriyuki Ashida, Tomohisa Nagamatsu, "*Synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins*" The 38th congress of heterocyclic chemistry, Fukuyama, Japan, 2008, Nov. 21~23, book abstract pp. 367-368.
82. **Hamed I. Ali**, S. Miura, T. Nagamatsu, "*Design, synthesis, and molecular docking affinity of 2-methylthio-5-deazaflavins, flavin-5-oxides, alloxazines, and their 2-n-(substituted amino) analogs as potent antitumor agents*". The 62nd Northwest Regional Meeting; NORM 2007, American Chemical Society, Boise, Idaho, USA, 2007, Jun. 17 ~ 20, book abstract p.58.
83. H. Nobusada, **Hamed I. Ali**, T. Fujita, S. Ohno, and T. Nagamatsu, "*The molecular design of fused pyrimidines as XO enzyme inhibitors aimed at therapeutic effect of gout*" The 27th Medicinal Chemistry symposium, Sagami, Kanagawa, Japan, Nov. 28–30, 2007. Oral presentation.
84. T. Nagamatsu, **Hamed I. Ali**, "*AutoDock Study of structure-activity relationship for flavin analogs based on antitumor activities and docking investigation into PTK*", The 37th Congress of Heterocyclic Chemistry, Nagamo, Japan, Oct. 17–19, 2007. Poster presentation.
85. **Ali, H. I.**; Tomita, K.; Akaho, E.; Miura, S.; Hayakawa, H.; Ashida, N.; Kawashima, Y.; Yamagishi, T.; Ikeya, H.; Yoneda, F.; Nagamatsu, T. "*Design, synthesis, activity and autodock study of novel 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as potent antitumor agents*", IKCOC10, The 10th International Kyoto Conference On New Aspects of Organic Chemistry, Kyoto, Japan, 2006, Nov.13 ~ 17, book abstract p.270.

86. T. Nagamatsu, **Hamed I. Ali**, K. Tomita, E. Akaho, H. Kambara, "Design of antitumor active flavin and 5-deazaflavin analogs and autodock study as ptkinhibitors" The 25th Medicinal Chemistry Symposium, Nagoya, Japan, 2006, Nov. 29~Dec.1, book abstract pp. 82-83.
87. **Hamed I. Ali**, T. Nagamatsu, "XO inhibitory activities and the structure-activity relationships by protein docking score for the fused triazolopyrimidines", Japan pharmaceutical society, Japan hospital pharmacist society, Shimane, Japan, 2004, Nov.6, 7, book abstract p.50.
88. T. Nagamatsu, **Hamed. I. Ali**, T. Fujita, Y. Gondai, K. Endo, M. Arita, H. Shimauchi, K. Sameshima, "Design and synthesis for fused [1,2,4]triazolo[1,5-c]-pyrimidine derivatives as potent xanthine oxidase inhibitors". Proceedings of the 6th Australia-Japan Symposium on Drug Design and Development, Sydney, Australia, 2004, Jun. 27~30, book abstract p.54
89. **Hamed Ali**, Hamad Hassan, Noriyuki Ashida, Eiichi Akaho, Tomohisa Nagamatsu, "Antitumor agents discovery by potential inhibition of tyrosine kinases involving docking approach". First International Medical Congress, Al-Beida-Libya, 2010, April. 23~25, book abstract p. 304.
90. **Hamed I. Ali**, Noriyuki Ashida, Eiichi Akaho, and Tomohisa Nagamatsu, "Novel approaches of drug discovery; design and synthesis of potent antitumor flavins and 5-deazaflavin analogues". First International pharmaceutical science conference, College of Pharmacy, Omar Al-Mukhtar Univ., Al-Beida-Libya, 2009, Dec. 22~24, book abstract p.1.
91. **Hamed I. Ali**, M. Yamada, Y. Fujita, Eiichi Akaho "Molecular modeling approach for regioselective binding mode of steroid molecules in homology modeled Cytochrome P450-2C11". First International pharmaceutical science conference, College of Pharmacy, Omar Al-Mukhtar Univ., Al-Beida-Libya, 2009, Dec. 22~24, book abstract p.179.
92. **Hamed I. Ali**, E. Akaho, H. Kambara, T. Nagamatsu. "An AutoDock strategy to search for enhanced protein tyrosine kinase inhibitors based on SAR" Kobe Gakuin Univ., College of pharmaceutical sciences, Kobe, Japan, 2006, Mar.13. Poster presentation.
93. **Hamed I. Ali**, E. Akaho, H. Kambara, T. Nagamatsu, "AutoDock study and structure-based drug design of potential protein tyrosine kinase inhibitors". Kobe Gakuin Univ., College of pharmaceutical sciences, Kobe, Japan, 2005, Oct. 8. Oral presentation.
94. **Hamed I. Ali**, "Structure-based design and AutoDock study for Tyrosine kinase inhibitors as potential antitumor agents". 1st congress of college of veterinary medicine, Omar Al-Mukhtar Univ., Al-Beida-Libya, 2010, Jul. 3~5, book abstract p.29.
95. **Hamed I. Ali**, Mohsen M. Kamel, M. M. Anwar, N. A. Mohamed, A. M. Soliman "Synthesis, antitumor activity and molecular docking study of novel sulfonamide-schiff's bases, thiazolidinones, benzothiazinones and their c-nucleoside derivatives". 1st congress of college of veterinary medicine, Omar Al-Mukhtar Univ., Al-Beida-Libya, 2010, Jul. 3~5, book abstract p.30.
96. **Hamed I. Ali**, E. Akaho, N. Ashida, and T. Nagamatsu, "Computer aided design, synthesis, antitumor activity, and molecular docking study of novel 2-substituted 2-deoxo-flavins, and 2-deoxoalloxazines and their 5-oxides and 5-deaza analogs as a new class of antitumor agents". 1st Scientific Conference of College of Pharmacy, Cairo Univ.. 2008, March 29, Cairo, Egypt.
97. M. S. Rizk, S. S. Toubar, and **Hamed. I. Ali**, "Fluorimetric determination of b-antibiotics by enhancement of fluorescence of ninhydrin / H₂O₂/ Co(II) ions", Aug. 2001. Helwan Univ., Cairo, Egypt.

98. M. S. Rizk, S. S. Toubar, and **Hamed. I. Ali**, "Spectrofluorimetric determination of aminoglycoside antibiotics through reaction with ninhydrin and Co(II) ions", Aug. 2001. Helwan Univ., Cairo, Egypt.

ACADEMIC SERVICES

Rangel College of Pharmacy, TAMHSC, USA

2017- present Co-supervisor for four Ph.D. students:

1. **Tamer Elwaie** (-Design, Synthesis, and Biological Screening of Novel Quinazolines as Selective Antitumor Hits; In Progress; 2019).
2. **Hussain Badshah** (Genetic Characterization and bio-accumulation analysis of wild Morels of different mountain range of Pakistan; Completed; 2018).
3. **Zartash Zahra** (Comprehending the Biological Potencies of *Lactuca dissecta* D. Don and *Vincetoxicum arnotianum* (Wight) Via in vitro and in vivo Investigation; Completed; 2019)
4. **Muhammad Majid** (Appraisal of Phytochemical and Pharmacological Prospective of *Ipomoea batatas* L. Lam; in Progress; 2019)

2016-present Member of the OAC (Outcome Assessment Committee)

2016-present Member of the Instructional Venues Advisory *Ad hoc* Committee

2015-2018 Interviewer for new applicants for Pharm-D program Class 2019-2022

2015-2018 Interviewer for new applicants for Pharm-D program Class 2019-2022

College of Pharmacy, Umm Al-Qura Univ., KSA

2011-2012 Head of Department of Clinical Pharmacy, and chair for Pharm-D module Accreditation.

2012-2013 Member of the Curriculum Committee.

2011-2012 Team Leader in the Department of Clinical Pharmacy, Self-Study Committee for Accreditation

2012-2013 Faculty Advisor for Pharm-D Program for Accreditation

2011-2012 Member of the College of Pharmacy and Graduate Affairs Committee.

2012-2013 Chair of the scientific committee, Department of Pharmaceutical Chemistry

2012-2013 Chair of the Student affair committee, Clinical Pharmacy Program (Pharm D)

College of Pharmacy, Helwan Univ., Cairo, Egypt

2008-2009 Unit Coordinator for the International Computer Driving license (ICDL), Helwan Univ.

2008-2009 Chair of the Scientific committee

2007-2008 Supervisor for the student union election, 3rd year pharmacy students.

2008-2009 Supervisor of Helwan Univ. student hostel in collaboration with the building manager

2007-2009 Member for committee of course specification for B-Pharm undergraduate students

2007-2009 Member for committee of course specification for B-Pharm undergraduate students and for the pharmaceutical chemistry modules

2008- 2013 Main supervisor for eight master pharmacy students, six of them have completed, and two are in progress.

1. **Duaa' Mohamed Sami Helmy** (*Molecular modeling based design and synthesis of potential*

- antitumor fused pteridine derivatives*), (Completed; 2011).
2. **Ahmed Mohamed Abdel Fattah** (*Molecular modeling and synthesis of benzo pteridin- eanlogs of prospected biological activity*), (Completed; 2012).
 3. **Sawsan Ahmed Shawkey** (*Design and synthesis of 5-deaza-alloxazine and their analogs of prospected biological activity based on computer aided drug design*), (Completed; 2012).
 4. **Walaa Abdul-Aziz Bedewy** (*Design, synthesis, and molecular docking study of novel substituted 5-deazaflavin analogues of proposed antitumor activity*), (Completed; 2012).
 5. **Ahmed M. Abbas Temirak** (*Drug design and synthesis of 2-heteroaryl benzimidazole derivatives of potential pharmacological activity*); (Completed; 2014).
 6. **Mohamed Khatab Fathy Khatab**(*Synthesis and docking studies of new 2-phenyl-benzimidazole of expected pharmacological activity*); (Completed; 2013).
 7. **Mona Abdullah Abdullaziz Mahmoud** (*Drug design and synthesis of new 2-furyl benzimidazoles of expected pharmacological activity*); (Completed; 2015).
 8. **Sara Hammad.** (Completed; 2018).

SCIENTIFIC JOURNAL AND RESEARCH PROJECT REVIEWER

1. European Journal of Medicinal Chemistry
2. Bioorganic & Medicinal Chemistry
3. International Journal of Molecular Sciences;
4. Computational Biology and Chemistry
5. Molecules
6. International Journal of Molecular Sciences
7. Egyptian Pharmaceutical Journal (EPJ)
8. Journal of Taibah University for Science

PHARMACY LICENTURE AND CERTIFICATION

2008-2009 Member of the committee of Helwan syndicate of pharmacists, Cairo, Egypt
1988-Present Registered Pharmacist in Cairo, Egypt.

TEACHING EXPERIENCES

I. UNDERGRADUATE and PROFESSIONAL (Pharm-D and B-Pharm) COURSES

1. Rangel College of Pharmacy, Texas A&M Univ. Health Science Center, USA.

Below is the list of courses that I taught over the past several years. I have an extensive experience in teaching all topics of Medicinal Chemistry, Drug Design, Drug Metabolism, Drug Interactions in professional curriculum of **Pharm-D program**. I also participated in recitations, pre-exam reviews, post-exam reviews, exams and other assessments in these courses.

PHAR610 **Principles of Drug Action I** (11 hrs. + Pre- and Post-exam Recitations)
(PharmY1) This course introduces basic principles of drug action and covers the properties (e.g., solubility), mechanisms of action, and structure-activity relationships of the major drug

- classes.
- PHAR611 (PharmY1) **Principles of Drug Action II** (9 hrs. + Pre- and Post-exam Recitations)
Cholinergic agonists and antagonists Med. Chem., AChE Inhibitors, Adrenergic agonists and antagonists Med. Chem.
- PHAR 734 (Elective) **Applied Drug Metabolism in Pharmacotherapy** (30 hrs. + Student Project + Pre- and Post-exam Recitations): This course handles the biotransformation reactions, the enzymes involved, and chemical, biological, and genetic factors that can affect drug-metabolizing enzymes and metabolic rates. In addition, it covers the metabolism-based drug-food, drug-disease, and drug-drug- interactions.
- PHAR712 (PharmY2) **IPT III: Endocrinology and Metabolic Diseases:** Corticosteroids and antidiabetic drugs (4 hrs.)
- PHAR713 (PharmY2) **IPT IV: Neurology and Pain Management**
Anti-Seizures, NSAIDs, Opioid analgesics (8 hrs. + Post-exam Recitations)
- PHAR810 (PharmY3) **IPT V: Psychiatry and Addiction:** (11 hrs). Sedatives, Hypnotics, and Anxiolytics, Antidepressants, Attention-deficit hyperactivity disorder drugs (ADHD), and Antischizophrenic drugs.
- PHAR811 (PharmY3) **IPT VI: GIT, Pulmonary, Rheumatic, Ophthalmology:** urinary Incontinence (1 hr), Peptic ulcer disease (pud), and gastroesophageal reflux disease (GERD) (1 hr), asthma, COPD and allergic rhinitis (2 hrs) and osteoarthritis, rheumatoid arthritis, and gout (2 hrs).
- PHAR812 (PharmY3) **IPT VII: Infectious Diseases:** Antibiotics (all classes), Antiviral, Anti-tuberculosis, Antifungal, Antiprotozoal (12 hrs. + Pre- and Post-exam Recitations)
- PHAR627 (30 hours) (PharmY1) **Biochemistry** (28 hrs. + Pre- and Post-exam Recitations)
Foundations of Biochemistry, Water, Amino acids, peptides, proteins, Protein Functions-Binding, Protein Functions-Catalysis, Carbohydrates, Nucleotides and Nucleic Acids, DNA-Based Information Technology, Lipids, Biological membranes and transport, Biosignaling, Bioenergetics, Glycolysis, gluconeogenesis, & the pentose phosphate, The Citric Acid Cycle, Fatty Acid Catabolism, Amino Acid Oxidation and Production of Urea, Oxidative Phosphorylation, Peptidoglycan Biosynthesis.

2. College of Arts and Sciences, Texas A&M Univ., Kingsville, USA (see Graduate Courses)

3. Misr International Univ. (MIU), College of Pharmacy, Egypt

- PHC 331 Chemotherapeutic agents (21 hrs., Spring 2009)
Antibiotics, Anti-Infective Agents, Antifungal antibiotics, Urinary Tract Anti-infective agents, Anti-T.B. Agents, Antiviral Agents, Antiprotozoal Agents, Anticancer Drugs
- PHC432 Central Nervous & Autonomic Nervous System Drugs, Analgesic drugs (14 hrs., Fall 2008)
(Narcotic & NSAIDs), Steroidal Hormones, Cardiovascular Drugs, Vitamins
- PHC 433 Practical pharmaceutical Pharmacopeial assays (7 hrs., Spring 2008)
- PHC 433 Drug Design & Drug Metabolism: (Total 44 hrs., Fall, Spring and Summer: 2008-2009).
Drug development by molecular manipulation, Quantitative structure activity relationship (QSAR), Soft & Hard drugs, Pro-drug (Drug Latentiation), Molecular modeling, Drug Biotransformation.

4. College of Pharmacy, Univ. of Modern Sciences and Arts (MSA), Egypt

- PC-331 Chemotherapeutic agents (15 hrs., Spring 2009)

- Anti-infective Agents, Urinary tract Antiseptics, Sulfonamides, Antiviral chemotherapeutics, Anti-mycobacterial drugs, Antifungal agents, Antiprotozoal Agents, Antibiotics, Histamine and antihistaminic Agents, Antineoplastic agents
- PC431 Centrally Acting Drugs (CNS Depressants & CNS Stimulants), Local (15 hrs., Summer 2008) Anesthetics, Autonomic Nervous System, Centrally Acting Analgesics, NSAIDs, Cardiovascular Drugs, Steroidal Hormones
- PC531 Drug Design & Drug Metabolism; (40 hrs., Fall, Spring 2008-2009)
Drug Development By Molecular manipulation, Quantitative Structure Activity Relationship (QSAR), Soft & Hard drugs, Pro-drugs, Molecular modeling, Drug Biotransformation.
- RS502 *Graduation Research Project*: (10 hrs., Spring 2009)
Synthesis & Molecular Docking Study of 2-deoxy-2-methylthioalloxazin-5-oxide, including Synthesis and computer aided drug design.

5. College of Pharmacy, Umm Al Qura Univ., Saudi Arabia

- Med. Chem.I (1805425) Drug Design ; Drug metabolism; (30 hrs., Fall 2010, 2011)
Antibiotics (β -Lactams, Amino-glycosides, Tetracyclines, Macrolides); Synthetic antibacterial (Quinolones and fluoroquinolones; sulphonamides); Anti-mycobacterial drugs; Antiviral drugs and anti-AIDS
- Med. Chem.II (1805526) CNS, ANS, CVS drugs (28 hrs., Spring 2010, 2011, 2012)
Antineoplastic agents; CNS stimulants; CNS depressants; Local anesthetics; Cardiovascular drugs; Diuretics; Adrenergic drugs; Cholinergic drugs; Analgesics (Opioid analgesics and NSAIDs); H₁-receptor antagonists; H₂-receptor antagonists; Antiulcer drugs.
- Med. Chem.III (1805527) Hormonal regulating Drugs (14 hrs., Fall 2012)
Drugs for metabolic diseases and endocrine functions; Steroid hormones: Female sex hormones; Male sex hormones and Adrenocorticoids; Insulin and anti-diabetic drugs;
- Med. Chem.IV & Q.C.(1805528) Drug metabolism; Oil and water soluble vitamins; (10 hrs., Fall 2012)
Clinically relevant medicinal chemistry; Quality control.

6. College of Pharmacy, Omar Al-Mukhtar Univ., Libya

- Clinical Pharmacy **Clinical Pharmacy & Therapeutics:** (40 hrs.; 2009-2010)
Cardiology & Cardiovascular Drugs, Hematology, Endocrinology, Diabetes Mellitus, Thyroid Disorders, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease, Asthma, Dermatology, Acne, Scabies.
- Drug Interaction **Drug Interaction & Drug Monitoring:** (26 hrs.; 2009-2010)
Pharmacodynamics & Pharmacokinetic Interactions, Drugs & Elderly, Drug Food Interactions, Herbal-Drug, Interactions, Drug Disease Interactions, Drug-Laboratory Interactions, Drug-Drug Interactions, Therapeutic Drug Monitoring.

7. College of Pharmaceutical Sciences, Okayama Univ., Japan

As a Teaching Assistant to demonstrate the techniques and assist students in the laboratory routines

- TA Practical Synthetic Organic Chemistry (22-24 hrs./year; 2003-2007)
TA Practical Pharmaceutical Chemistry (22-24 hrs./year; 2003-2007).

8. College of Pharmacy, Helwan Univ., Cairo, Egypt

As a Teaching Assistant, Instructor, Lecturer, and then Associate Professor

- Pharm.Chem.1 Antineoplastic agents, Tetracycline antibiotics , Antiviral drugs, Anti-tuberculous agents, Anti-leprotic agents. (18 hrs.; Spring 2008, 2009)
- Pharm.Chem.2 Drug Development By Molecular manipulation, Quantitative Structure Activity Relationship (QSAR), Hard And soft drugs, Prodrugs, Molecular modeling, Drug Biotransformation (22 hrs; Fall 2008, 2009).
- Pharm.Chem.3 NSAIDs, Narcotic Analgesics, Local Anesthetics, Antihistaminic Drugs (12 hrs.; Fall & Spring 2008, 2009)
- Pharm.Chem.4 Autonomic Nervous System, Anti-parkinsonian drugs, Centrally Acting Drugs (CNS depressants & CNS Stimulants), Cardio Vascular Agents (10 hrs.; Spring 2009)
- Org. Chem1, 2 Practical Organic chemistry (24 hrs.; fall & Spring 1995-1999)
- Anal. Chem. 2 Practical Analytical Chemistry (72 hrs.; fall & Spring 1997-1999)

9. College of Pharmacy, Tanta Univ., Egypt

As a Teaching Assistant, to demonstrate techniques and assisted students in every day laboratory routines and graded laboratory write-ups.

- Pharm.Chem.1,2 Practical Pharmaceutical Chemistry1,2 (36 hrs.; fall & Spring 1991-1994)
- Drug Des.4 Practical Drug Design (36 hrs.; Spring 1992-1994)
- Bioch.1,2 Practical Biochemistry (36 hrs.; fall 1992-1993)
- Org. Chem1,2 Practical Organic chemistry (36 hrs.; fall & Spring 1991-1994)
- Anal. Chem Practical Analytical Chemistry (24 hrs.; Spring 1991-1994)
- Fron. Chem Practical Forensic Chemistry (24 hrs.; fall 1991-1994)

II. GRADUATE/PROFESSIONAL COURSES

For graduate students I taught topics in advanced Medicinal Chemistry, drug design and targeting, SAR, and Pro-drugs, in addition to Modern techniques of drug discovery.

- Master students College of Arts and Sciences, Texas A&M Univ., Kingsville, USA
Graduate Level Pharmaceutical Chemistry Course (9 hrs., 2013 Spring)
Drug Action, Drug Discovery, Drug Design and Development By Molecular manipulation, Quantitative Structure Activity Relationship (QSAR), Soft & Hard drugs, Pro-drugs.
- Master students College of Pharmacy, Helwan Univ., Cairo, Egypt (12 hrs.; Spring 2009)
Advanced medicinal chemistry, Drug design, computer aided Drug design:
- Ph.D. students College of Pharmacy, Helwan Univ., Cairo, Egypt (16 hrs.; Spring 2009)
Advanced medicinal chemistry, Drug Discovery, Drug design, Computational Chemistry (16 hrs.; Spring 2009).

UNIVERSITY BOOK CHAPTERS

- 2009-2010 Drug Design for 5th year students (MSA Univ.).
- 2007-2008 Pharmaceutical chemistry I for 4th year pharmacy students, 1st semester. (Helwan Univ.)
- 2007-2008 Pharmaceutical chemistry II for 4th year pharmacy students, 2nd semester. (Helwan Univ)
- 2008-2009 Pharmaceutical chemistry III for 5th year pharmacy students, 1st semester. (Helwan Univ)
- 2007-2008 Lab. manual of Pharmaceutical chemistry II for 4th year pharmacy students, 1st semester (Helwan Univ.)

2008-2009 Lab. manual of Pharmaceutical chemistry III for 5th year pharmacy students, 1st semeste (Helwan Univ.)

WORKSHOPS/ PROFESSIONAL TRAINING

April 17-18, 2018 Transformational Teaching and Learning Conference (TTLC), Texas A&M University. Room 2300 of the Memorial Student Center.

Sep. 21-22, 2017 Write Winning Grant Proposals Grant Writers' Seminars & Workshops.

Friday, 21, 2017 2017 TPA-NCPA's first Patient Counseling Competition judge.

Mar. 31-Apr. 2, 2017 20th Annual Teaching & Learning in Higher Education "Activating Student Learning". Wakonse South Conference South Conference. Pedagogy project: Center for Teaching Excellence Texas A&M University.

Feb. 7, 2017 ORCID work flow and Scholars@TAMU, College of Pharmacy.

Dec 15, 2016. Faculty Forum, Rangel College of Pharmacy, ExamSoft Best practices; Tagging Tagging ExamSoft questions; PCOA Blueprint and Collapsed Bloom's Taxonomy

Oct. 21, 2016 Measuring Student Learning Outcomes with ExamSoft Categories workshop.

June 7, 2016 Product Development and Implications of Product Quality on Therapeutic Outcomes

May 19, 2016 AACP webinar: How to Find and Apply for Corporate and Foundation Funding Opportunities

April 29, 2016 Exam Question Writing Workshop at TAMHSC, Rangel College of Pharmacy.

April 29, 2016 Superior Multiple Choice Exam Item Construction and Analysis; TAMU Center for Teaching Excellence

April 28, 2016 Student Learning – Let's have a discussion. Dr. J. Doug Bricker.

April 26, 2016 Boost Your Career to a National Level with Social Media; Dr. Nicki Hilliard

2016 Scholarly Impact and Profile Series (1) Biosketch Made Easy, by Dr. Lin Wu; Medical Science Library.

Feb. 25-26, 2016 General faculty Retreat, Texas A&M Rangel College of Pharmacy

Dec 3, 2015 Teaching Methods and Approaches to Engage Students; Location: MSC 1400. Presenter/Instructor: Dr. Nate Poling, Center for Teaching Excellence

Sept. 18, 2015 Flipped Teaching + Self –Regulated Learning Faculty development workshop, at Texas A&M Health Science Center, Irma Lerma Rangel College of Pharmacy

Feb 2015 NIH workshop "Write Winning NIH Grant Proposals" COP 247; Feb 2015; Seminar Sponsored by the Division of Research.

2-3 Oct., 2014 NIH Grant Writing Workshop

6-9 Aug., 2014 Women and Underrepresented Postdoc, Graduate Student, and Early Career Faculty Institute at Texas A&M University; Texas A&M University, Health Professional Education Building (HPEB), College of Medicine, Bryan, TX, 77807

24 Jul.,2014 Faculty Development Workshop: "Engaging Students from Start to Finish" Presented by: The Teaching Learning Resource Center

10 Jul., 2014 Workshop of "Engaging Students in a Videoconference Environment" sponsored by Rangel College of Pharmacy, Texas A&M University,

15 May, 2014 Faculty Development Workshop: "Writing Meaningful Learning Objectives" Presented by: The Teaching Learning Resource Center

26-28 Jul.,2011 Conference organization

2-8 Aug.,2011 Time and Conference Management

Hamed I. Ali, BSPharm, MSPharm, PhD. C.V.

14-16 Aug.,2011 Effective presentation skills
21-23 Aug.,2011 Effective Communication Skills
23-25 Aug.,2011 Student Evaluation
21-23 Jan.,2013 Use of Technology in Teaching

LANGUAGES

English Proficiency:
Arabic mother tongue
Primitive German, and Japanese languages

PROFESSIONAL AFFILIATIONS

American Association of Pharmaceutical Scientists (AAPS), member ID: 223287
American Chemical Society (ACS), member No. 30640786
American Association for Cancer Research (AACR), member ID: 316397
American Association of Colleges of Pharmacy (AACP), member ID: 91493
Organizing Committee of MALTO-Medicinal Chemistry and Pharmacognosy
General Syndicate of Pharmacists, Egypt
Cairo Pharmacists Syndicate, Egypt

MEDIA INTERVIEWS

The Kingsville Record and Bishop News: Wednesday, Jul. 17, 2013. SOUTH TEXAS RESEARCHERS HIGHLIGHT PROJECTS. The first place for the poster competition on *“Computer Aided Drug Design of Novel Allosteric Modulators of CB1 Receptor”*

[..\Awards 2017\KV071713A7.pdf](#)

The South Texan, Thursday, Oct. 26, 2017. On the path to a cure. Dr. Ali designing, testing drug to fight cancer. Page 1 and 6.

https://issuu.com/thesouthtexan/docs/issue_10_26

Kiii.tv South Texas: A&M Kingsville researchers working on new medicines. Researchers at A & M Kingsville working on new medicines that will help leukemia and breast cancer patients. New medication research for cancer patients Cancer research:

<https://www.kiiitv.com/article/news/local/am-kingsville-researchers-working-on-new-medicines/481691362>